Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond

Nature Reviews Drug Discovery

Volumn 11, Issue 4, 2012, Pages 311-331

  Hogarth, P Mark ^a,b,c   Pietersz, Geoffrey A ^a,b,c  

^a BURNET INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIBODY; CD64 ANTIGEN; FC GAMMA RECEPTOR IIC; FC GAMMA RECEPTOR IIIA; FC GAMMA RECEPTOR IIIB; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIB; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3G8; OFATUMUMAB; RITUXIMAB; UNCLASSIFIED DRUG;

ANTIBODY COMBINING SITE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNE DISEASE; BINDING AFFINITY; BINDING SITE; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; COMPLEX FORMATION; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; GLYCOSYLATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; INFLAMMATORY DISEASE; INTERMETHOD COMPARISON; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTORS, FC;

EID: 84859301570     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2909     Document Type: Review

References (169)

1. Hulett, M. D. & Hogarth, P. M. Molecular basis of Fc receptor function. Adv. Immunol. 57, 1-127 (1994).
2. Nakamura, A., Akiyama, K. & Takai, T. Fc receptor targeting in the treatment of allergy, autoimmune diseases and cancer. Expert Opin. Ther. Targets 9, 169-190 (2005).
3. Takai, T. Fc receptors and their role in immune regulation and autoimmunity. J. Clin. Immunol. 25, 1-18 (2005).
4. Cady, C. T. et al. IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcγgRIIA and FcγgRIIB. Immunol. Lett. 130, 57-65 (2010).
5. Hamerman, J. A. et al. Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J. Immunol. 177, 2051-2055 (2006).
6. Pfirsch-Maisonnas, S. et al. Inhibitory ITAM signaling traps activating receptors with the phosphatase SHP-1 to form polarized "inhibisome" clusters. Sci. Signal. 4, ra24 (2011).
7. Pinheiro da Silva, F. et al. CD16 promotes Escherichia coli sepsis through an FcRγ inhibitory pathway that prevents phagocytosis and facilitates inflammation. Nature Med. 13, 1368-1374 (2007).
8. Nimmerjahn, F. & Ravetch, J. V. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310, 1510-1512 (2005).
9. Ravetch, J. In vivo veritas: the surprising roles of Fc receptors in immunity. Nature Immunol. 11, 183-185 (2010).
10. Metzger, H. Transmembrane signaling: the joy of aggregation. J. Immunol. 149, 1477-1487 (1992).
11. Ramsland, P. A. et al. Structural basis for FcγRIIa recognition of human IgG and formation of inflammatory signaling complexes. J. Immunol. 187, 3208-3217 (2011).
12. Powell, M. S. et al. Alteration of the FcγRIIa dimer interface affects receptor signaling but not ligand binding. J. Immunol. 176, 7489-7494 (2006).
13. Maxwell, K. F. et al. Crystal structure of the human leukocyte Fc receptor, FcγRIIa. Nature Struct. Biol. 6, 437-442 (1999).
14. Acharya, M. et al. CD23/FcεeRII: molecular multi-tasking. Clin. Exp. Immunol. 162, 12-23 (2010).
15. Wines, B. D., Powell, M. S., Parren, P. W., Barnes, N. & Hogarth, P. M. The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors FcγRI and FcγαRIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A. J. Immunol. 164, 5313-5318 (2000).
16. + dendritic cells. Proc. Natl Acad. Sci. USA 108, 9927-9932 (2011).
17. Kacskovics, I., Cervenak, J., Erdei, A., Goldsby, R. A. & Butler, J. E. Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies. MAbs 3, 431-439 (2011).
18. Vaccaro, C., Zhou, J., Ober, R. J. & Ward, E. S. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nature Biotech. 23, 1283-1288 (2005).
19. van der Poel, C. E. et al. Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcγRI, in the presence of monomeric IgG. Blood 116, 5327-5333 (2010).
20. Bruhns, P. et al. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood 113, 3716-3725 (2009).
21. Maenaka, K., van der Merwe, P. A., Stuart, D. I., Jones, E. Y. & Sondermann, P. The human low affinity Fcγ receptors IIa, IIb, and III bind IgG with fast kinetics and distinct thermodynamic properties. J. Biol. Chem. 276, 44898-44904 (2001).
22. Powell, M. S. et al. Biochemical analysis and crystallisation of FcγRIIa, the low affinity receptor for IgG. Immunol. Lett. 68, 17-23 (1999).
23. Bibeau, F. et al. Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol. 27, 1122-1129 (2009).
24. Concetti, F. & Napolioni, V. Insights into the role of Fcγ receptors (FcγRs) genetic variations in monoclonal antibody-based anti-cancer therapy. Recent Pat. Anticancer Drug Discov. 5, 197-204 (2010).
25. Zhuang, Y., Xu, W., Shen, Y. & Li, J. Fcγ receptor polymorphisms and clinical efficacy of rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Clin. Lymphoma Myeloma Leuk. 10, 347-352 (2010).
26. Cady, C. T., Rice, J. S., Ott, V. L. & Cambier, J. C. Regulation of hematopoietic cell function by inhibitory immunoglobulin G receptors and their inositol lipid phosphatase effectors. Immunol. Rev. 224, 44-57 (2008).
27. Burton, D. R. & Woof, J. M. Human antibody effector function. Adv. Immunol. 51, 1-84 (1992).
28. Matsumiya, S. et al. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J. Mol. Biol. 368, 767-779 (2007).
29. Radaev, S., Motyka, S., Fridman, W. H., Sautes-Fridman, C. & Sun, P. D. The structure of a human type III Fcγ receptor in complex with Fc. J. Biol. Chem. 276, 16469-16477 (2001).
30. Radaev, S. & Sun, P. D. Recognition of IgG by Fcγ receptor. The role of Fc glycosylation and the binding of peptide inhibitors. J. Biol. Chem. 276, 16478-16483 (2001).
31. Sondermann, P., Huber, R., Oosthuizen, V. & Jacob, U. The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex. Nature 406, 267-273 (2000).
32. Sondermann, P. & Oosthuizen, V. X-ray crystallographic studies of IgG-Fcγ receptor interactions. Biochem. Soc. Trans. 30, 481-486 (2002).
33. Lu, J., Ellsworth, J. L., Hamacher, N., Oak, S. W. & Sun, P. D. Crystal structure of Fcγ receptor I and its implication in high affinity γ-immunoglobulin binding. J. Biol. Chem. 286, 40608-40613 (2011).
34. Garman, S. C., Wurzburg, B. A., Tarchevskaya, S. S., Kinet, J. P. & Jardetzky, T. S. Structure of the Fc fragment of human IgE bound to its high-affinity receptor FcεeRIα. Nature 406, 259-266 (2000).
35. Wines, B. D., Sardjono, C. T., Trist, H. H., Lay, C. S. & Hogarth, P. M. The interaction of FcαRI with IgA and its implications for ligand binding by immunoreceptors of the leukocyte receptor cluster. J. Immunol. 166, 1781-1789 (2001).
36. Herr, A. B., Ballister, E. R. & Bjorkman, P. J. Insights into IgA-mediated immune responses from the crystal structures of human FcαRI and its complex with IgA1-Fc. Nature 423, 614-620 (2003).
37. Takai, T., Li, M., Sylvestre, D., Clynes, R. & Ravetch, J. V. FcRγ chain deletion results in pleiotrophic effector cell defects. Cell 76, 519-529 (1994).
38. Pritchard, N. R. et al. Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcγRII. Curr. Biol. 10, 227-230 (2000).
39. Ierino, F. L., Powell, M. S., McKenzie, I. F. & Hogarth, P. M. Recombinant soluble human FcγRII: production, characterization, and inhibition of the Arthus reaction. J. Exp. Med. 178, 1617-1628 (1993).
40. b mice susceptible to collagen-induced arthritis. J. Exp. Med. 189, 187-194 (1999).
41. Tan Sardjono, C. et al. Development of spontaneous multisystem autoimmune disease and hypersensitivity to antibody-induced inflammation in Fcγ receptor IIa-transgenic mice. Arthritis Rheum. 52, 3220-3229 (2005).
42. van Lent, P. L. et al. Role of Fc receptor γ chain in inflammation and cartilage damage during experimental antigen-induced arthritis. Arthritis Rheum. 43, 740-752 (2000).
43. van Lent, P. L. et al. Role of activatory FcγRI and FcγααRIII and inhibitory FcγRII in inflammation and cartilage destruction during experimental antigen-induced arthritis. Am. J. Pathol. 159, 2309-2320 (2001).
44. Mullazehi, M., Mathsson, L., Lampa, J. & Ronnelid, J. Surface-bound anti-type II collagen-containing immune complexes induce production of tumor necrosis factor α, interleukin-1β, and interleukin-8 from peripheral blood monocytes via Fcγ receptor IIA: a potential pathophysiologic mechanism for humoral anti-type II collagen immunity in arthritis. Arthritis Rheum. 54, 1759-1771 (2006).
45. Ravetch, J. V. Fc receptors: rubor redux. Cell 78, 553-560 (1994).
46. Tsuboi, N., Asano, K., Lauterbach, M. & Mayadas, T. N. Human neutrophil Fcγ receptors initiate and play specialized nonredundant roles in antibody-mediated inflammatory diseases. Immunity 28, 833-846 (2008).
47. Monach, P. A., Benoist, C. & Mathis, D. The role of antibodies in mouse models of rheumatoid arthritis, and relevance to human disease. Adv. Immunol. 82, 217-248 (2004).
48. Diaz de Stahl, T., Andren, M., Martinsson, P., Verbeek, J. S. & Kleinau, S. Expression of FcγRIII is required for development of collagen-induced arthritis. Eur. J. Immunol. 32, 2915-2922 (2002).
49. Barnes, N. et al. FcγRI-deficient mice show multiple alterations to inflammatory and immune responses. Immunity 16, 379-389 (2002).
50. Baudino, L. et al. Differential contribution of three activating IgG Fc receptors (FcγRI, FcγRIII, and FcγRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice. J. Immunol. 180, 1948-1953 (2008).
51. Bergtold, A., Gavhane, A., D'Agati, V., Madaio, M. & Clynes, R. FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis. J. Immunol. 177, 7287-7295 (2006).
52. Ioan-Facsinay, A. et al. FcγRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 16, 391-402 (2002).
53. McKenzie, S. E. Humanized mouse models of FcR clearance in immune platelet disorders. Blood Rev. 16, 3-5 (2002).
54. Nimmerjahn, F. & Ravetch, J. V. Fcγ receptors as regulators of immune responses. Nature Rev. Immunol. 8, 34-47 (2008).
55. Nimmerjahn, F. & Ravetch, J. V. Antibody-mediated modulation of immune responses. Immunol. Rev. 236, 265-275 (2010).
56. Takai, T. Allergy and autoimmunity mediated by IgG and Fcγ receptors. Arerugi 54, 1183-1189 (2005).
57. McGaha, T. L., Karlsson, M. C. & Ravetch, J. V. FcγRIIB deficiency leads to autoimmunity and a defective response to apoptosis in Mrl-MpJ mice. J. Immunol. 180, 5670-5679 (2008).
58. Dharajiya, N. et al. FcγRIIb inhibits allergic lung inflammation in a murine model of allergic asthma. PLoS ONE 5, e9337 (2010).
59. Clatworthy, M. R. et al. Systemic lupus erythematosus-associated defects in the inhibitory receptor FcγRIIb reduce susceptibility to malaria. Proc. Natl Acad. Sci. USA 104, 7169-7174 (2007).
60. Tsuboi, N. et al. Regulation of human neutrophil Fcγ receptor IIa by C5a receptor promotes inflammatory arthritis in mice. Arthritis Rheum. 63, 467-478 (2011).
61. Van de Velde, N. C. et al. Transgenic mice expressing human FcγRIIa have enhanced sensitivity to induced autoimmune arthritis as well as elevated Th17 cells. Immunol. Lett. 130, 82-88 (2010).
62. Means, T. K. et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 115, 407-417 (2005).
63. Asano, K. et al. A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. Nature Genet. 41, 1325-1329 (2009).
64. Hogarth, P. M. Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr. Opin. Immunol. 14, 798-802 (2002).
65. Ellsworth, J. L. et al. Recombinant soluble human FcγR1A (CD64A) reduces inflammation in murine collagen-induced arthritis. J. Immunol. 182, 7272-7279 (2009).
66. Ellsworth, J. L. et al. Generation of a high-affinity Fcγ receptor by Ig-domain swapping between human CD64A and CD16A. Protein Eng. Des. Sel. 23, 299-309 (2010).
67. Ellsworth, J. L. et al. Targeting immune complex-mediated hypersensitivity with recombinant soluble human FcγRIA (CD64A). J. Immunol. 180, 580-589 (2008).
68. Magnusson, S. E. et al. Amelioration of collagen-induced arthritis by human recombinant soluble FcγRIIb. Clin. Immunol. 127, 225-233 (2008).
69. Shashidharamurthy, R. et al. Extravasations and emigration of neutrophils to the inflammatory site depend on the interaction of immune-complex with Fcγ receptors and can be effectively blocked by decoy Fcγ receptors. Blood 111, 894-904 (2008).
70. Werwitzke, S. et al. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fcγ receptor II (CD32). Ann. Rheum. Dis. 67, 154-161 (2008).
71. Dougherty, G. J., Selvendran, Y., Murdoch, S., Palmer, D. G. & Hogg, N. The human mononuclear phagocyte high-affinity Fc receptor, FcRI, defined by a monoclonal antibody, 10.1. Eur. J. Immunol. 17, 1453-1459 (1987).
72. Fleit, H. B., Wright, S. D. & Unkeless, J. C. Human neutrophil Fcγ receptor distribution and structure. Proc. Natl Acad. Sci. USA 79, 3275-3279 (1982).
73. Looney, R. J., Abraham, G. N. & Anderson, C. L. Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J. Immunol. 136, 1641-1647 (1986).
74. Rankin, C. T. et al. CD32B, the human inhibitory Fc-γ receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma. Blood 108, 2384-2391 (2006).
75. Su, K. et al. Expression profile of FcγRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J. Immunol. 178, 3272-3280 (2007).
76. Kimberly, R. P. et al. In vivo handling of soluble complement fixing Ab/dsDNA immune complexes in chimpanzees. J. Clin. Invest. 84, 962-970 (1989).
77. Clarkson, S. B. et al. Treatment of refractory immune thrombocytopenic purpura with an anti-Fcγ-receptor antibody. N. Engl. J. Med. 314, 1236-1239 (1986).
78. Clarkson, S. B. et al. Blockade of clearance of immune complexes by an anti-Fcγ receptor monoclonal antibody. J. Exp. Med. 164, 474-489 (1986).
79. Ericson, S. G. et al. Monoclonal antibody 197 (anti-FcγRI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of FcγRI on circulating monocytes. Br. J. Haematol. 92, 718-724 (1996).
80. Wallace, P. K. et al. Humanized mAb H22 binds the human high affinity Fc receptor for IgG (FcγRI), blocks phagocytosis, and modulates receptor expression. J. Leukoc. Biol. 62, 469-479 (1997).
81. Smith, K. G. & Clatworthy, M. R. FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nature Rev. Immunol. 10, 328-343 (2010).
82. Li, X. et al. A novel polymorphism in the Fcγ receptor IIB (CD32B) transmembrane region alters receptor signaling. Arthritis Rheum. 48, 3242-3252 (2003).
83. Kyogoku, C. et al. Fcγ receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum. 46, 1242-1254 (2002).
84. Alizadeh, B. Z. et al. Association analysis of functional variants of the FcγRIIa and FcγRIIIa genes with type 1 diabetes, celiac disease and rheumatoid arthritis. Hum. Mol. Genet. 16, 2552-2559 (2007).
85. Harley, J. B. et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nature Genet. 40, 204-210 (2008).
86. Weersma, R. K. et al. Association of FcγR2a, but not FcγR3a, with inflammatory bowel diseases across three Caucasian populations. Inflamm. Bowel Dis. 16, 2080-2089 (2010).
87. Fanciulli, M. et al. FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nature Genet. 39, 721-723 (2007).
88. Niederer, H. A. et al. Copy number, linkage disequilibrium and disease association in the FCGR locus. Hum. Mol. Genet. 19, 3282-3294 (2010).
89. Nakamura, G. R., Reynolds, M. E., Chen, Y. M., Starovasnik, M. A. & Lowman, H. B. Stable "zeta" peptides that act as potent antagonists of the high-affinity IgE receptor. Proc. Natl Acad. Sci. USA 99, 1303-1308 (2002).
90. Nakamura, G. R., Starovasnik, M. A., Reynolds, M. E. & Lowman, H. B. A novel family of hairpin peptides that inhibit IgE activity by binding to the high-affinity IgE receptor. Biochemistry 40, 9828-9835 (2001).
91. Rigby, L. J. et al. Monoclonal antibodies and synthetic peptides define the active site of FcεRI and a potential receptor antagonist. Allergy 55, 609-619 (2000).
92. Ciccimarra, F., Rosen, F. S. & Merler, E. Localization of the IgG effector site for monocyte receptors. Proc. Natl Acad. Sci. USA 72, 2081-2083 (1975).
93. Ratcliffe, A. & Stanworth, D. R. The use of synthetic γ-chain peptides in the localization of the binding site(s) on human IgG1 for the Fc receptors of homologous monocytes and heterologous mouse macrophages. Immunol. Lett. 4, 215-221 (1982).
94. Sondermann, P. & Oosthuizen, V. The structure of Fc receptor/Ig complexes: considerations on stoichiometry and potential inhibitors. Immunol. Lett. 82, 51-56 (2002).
95. Verdoliva, A. et al. A new ligand for immunoglobulin G subdomains by screening of a synthetic peptide library. Chembiochem 6, 1242-1253 (2005).
96. Berntzen, G. et al. Characterization of an FcγRI-binding peptide selected by phage display. Protein Eng. Des. Sel. 19, 121-128 (2006).
97. DeLano, W. L., Ultsch, M. H., de Vos, A. M. & Wells, J. A. Convergent solutions to binding at a protein-protein interface. Science 287, 1279-1283 (2000).
98. Boonyarattanakalin, S., Martin, S. E., Sun, Q. & Peterson, B. R. A synthetic mimic of human Fc receptors: defined chemical modification of cell surfaces enables efficient endocytic uptake of human immunoglobulin-G. J. Am. Chem. Soc. 128, 11463-11470 (2006).
99. Bonetto, S., Spadola, L., Buchanan, A. G., Jermutus, L. & Lund, J. Identification of cyclic peptides able to mimic the functional epitope of IgG1-Fc for human FcγRI. FASEB J. 23, 575-585 (2009).
100. Berntzen, G. et al. Identification of a high affinity FcγRIIA-binding peptide that distinguishes FcγRIIA from FcγRIIB and exploits FcγRIIA-mediated phagocytosis and degradation. J. Biol. Chem. 284, 1126-1135 (2009).
101. Cendron, A. C. et al. An FcγRIIa-binding peptide that mimics the interaction between FcγRIIa and IgG. Mol. Immunol. 45, 307-319 (2008).
102. Pietersz, G. A. et al. Inhibition of destructive autoimmune arthritis in FcγRIIa transgenic mice by small chemical entities. Immunol. Cell Biol. 87, 3-12 (2009).
103. Williams, R. O., Feldmann, M. & Maini, R. N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl Acad. Sci. USA 89, 9784-9788 (1992).
104. Braselmann, S. et al. R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation. J. Pharmacol. Exp. Ther. 319, 998-1008 (2006).
105. Podolanczuk, A., Lazarus, A. H., Crow, A. R., Grossbard, E. & Bussel, J. B. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 113, 3154-3160 (2009).
106. Jolles, S., Sewell, W. A. & Misbah, S. A. Clinical uses of intravenous immunoglobulin. Clin. Exp. Immunol. 142, 1-11 (2005).
107. Baerenwaldt, A., Biburger, M. & Nimmerjahn, F. Mechanisms of action of intravenous immunoglobulins. Expert Rev. Clin. Immunol. 6, 425-434 (2010).
108. Ballow, M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J. Allergy Clin. Immunol. 127, 315-323 (2011).
109. Viard, I. et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282, 490-493 (1998).
110. Bayary, J. et al. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. Int. Immunopharmacol. 6, 528-534 (2006).
111. Crow, A. R., Song, S., Siragam, V. & Lazarus, A. H. Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia. Pediatr. Blood Cancer 47 (Suppl. 5), 710-713 (2006).
112. Debre, M. et al. Infusion of Fcγ fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342, 945-949 (1993).
113. Siragam, V. et al. Intravenous immunoglobulin ameliorates ITP via activating Fcγ receptors on dendritic cells. Nature Med. 12, 688-692 (2006).
114. Kaneko, Y., Nimmerjahn, F. & Ravetch, J. V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313, 670-673 (2006).
115. H2 pathway. Nature 475, 110-113 (2011).
116. Jefferis, R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol. Sci. 30, 356-362 (2009).
117. Jefferis, R. Glycosylation as a strategy to improve antibody-based therapeutics. Nature Rev. Drug Discov. 8, 226-234 (2009).
118. Routier, F. H. et al. Quantitation of the oligosaccharides of human serum IgG from patients with rheumatoid arthritis: a critical evaluation of different methods. J. Immunol. Methods 213, 113-130 (1998).
119. Cartron, G. et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99, 754-758 (2002).
120. Oflazoglu, E. & Audoly, L. P. Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. MAbs 2, 14-19 (2010).
121. Weng, W. K. & Levy, R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21, 3940-3947 (2003).
122. Cheung, N. K. et al. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J. Clin. Oncol. 24, 2885-2890 (2006).
123. Koene, H. R. et al. FcγRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcγRIIIa, independently of the FcγRIIIa-148L/R/H phenotype. Blood 90, 1109-1114 (1997).
124. Weng, W. K., Czerwinski, D., Timmerman, J., Hsu, F. J. & Levy, R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J. Clin. Oncol. 22, 4717-4724 (2004).
125. Farag, S. S. et al. FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 103, 1472-1474 (2004).
126. Lin, T. S. et al. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood 105, 289-291 (2005).
127. de Haij, S. et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res. 70, 3209-3217 (2010).
128. Hamaguchi, Y., Xiu, Y., Komura, K., Nimmerjahn, F. & Tedder, T. F. Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203, 743-753 (2006).
129. Lim, S. H. et al. Fcγ receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 118, 2530-2540 (2011).
130. Lazar, G. A. et al. Engineered antibody Fc variants with enhanced effector function. Proc. Natl Acad. Sci. USA 103, 4005-4010 (2006).
131. Burton, D. R. et al. The Clq receptor site on immunoglobulin G. Nature 288, 338-344 (1980).
132. Stavenhagen, J. B. et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγ receptors. Cancer Res. 67, 8882-8890 (2007).
133. Stavenhagen, J. B. et al. Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization. Adv. Enzyme Regul. 48, 152-164 (2008).
134. Shields, R. L. et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J. Biol. Chem. 276, 6591-6604 (2001).
135. Albert, H., Collin, M., Dudziak, D., Ravetch, J. V. & Nimmerjahn, F. In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc. Natl Acad. Sci. USA 105, 15005-15009 (2008).
136. Lifely, M. R., Hale, C., Boyce, S., Keen, M. J. & Phillips, J. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 5, 813-822 (1995).
137. Umana, P., Jean-Mairet, J., Moudry, R., Amstutz, H. & Bailey, J. E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nature Biotech. 17, 176-180 (1999).
138. Shields, R. L. et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277, 26733-26740 (2002).
139. Shinkawa, T. et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278, 3466-3473 (2003).
140. Yamane-Ohnuki, N. et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol. Bioeng. 87, 614-622 (2004).
141. Ferrara, C. et al. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous β1, 4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II. Biotechnol. Bioeng. 93, 851-861 (2006).
142. Ferrara, C., Stuart, F., Sondermann, P., Brunker, P. & Umana, P. The carbohydrate at FcγRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J. Biol. Chem. 281, 5032-5036 (2006).
143. Hodoniczky, J., Zheng, Y. Z. & James, D. C. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol. Prog. 21, 1644-1652 (2005).
144. Schuster, M. et al. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. Cancer Res. 65, 7934-7941 (2005).
145. van Berkel, P. H. et al. Rapid production of recombinant human IgG with improved ADCC effector function in a transient expression system. Biotechnol. Bioeng. 105, 350-357 (2010).
146. Yamamoto, K. et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J. Clin. Oncol. 28, 1591-1598 (2010).
147. Sazinsky, S. L. et al. Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc. Natl Acad. Sci. USA 105, 20167-20172 (2008).
148. Ward, E. S. & Ober, R. J. Chapter 4. Multitasking by exploitation of intracellular transport functions: the many faces of FcRn. Adv. Immunol. 103, 77-115 (2009).
149. Mezo, A. R., Sridhar, V., Badger, J., Sakorafas, P. & Nienaber, V. X-ray crystal structures of monomeric and dimeric peptide inhibitors in complex with the human neonatal Fc receptor, FcRn. J. Biol. Chem. 285, 27694-27701 (2010).
150. West, A. P. Jr & Bjorkman, P. J. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor. Biochemistry 39, 9698-9708 (2000).
151. Stapleton, N. M. et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nature Commun. 2, 599 (2011).
152. Hinton, P. R. et al. Engineered human IgG antibodies with longer serum half-lives in primates. J. Biol. Chem. 279, 6213-6216 (2004).
153. Dall'Acqua, W. F., Kiener, P. A. & Wu, H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem. 281, 23514-23524 (2006).
154. Kenanova, V. et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res. 65, 622-631 (2005).
155. Vaccaro, C., Bawdon, R., Wanjie, S., Ober, R. J. & Ward, E. S. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc. Natl Acad. Sci. USA 103, 18709-18714 (2006).
156. Prabhat, P. et al. Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy. Proc. Natl Acad. Sci. USA 104, 5889-5894 (2007).
157. Kurlander, R. J. Blockade of Fc receptor-mediated binding to U-937 cells by murine monoclonal antibodies directed against a variety of surface antigens. J. Immunol. 131, 140-147 (1983).
158. Hamerman, J. A. & Lanier, L. L. Inhibition of immune responses by ITAM-bearing receptors. Sci. STKE 2006, re1 (2006).
159. Dunn-Siegrist, I. et al. Pivotal involvement of Fcγ receptor IIA in the neutralization of lipopolysaccharide signaling via a potent novel anti-TLR4 monoclonal antibody 15C1. J. Biol. Chem. 282, 34817-34827 (2007).
160. O'Neill, S. K. et al. Monophosphorylation of CD79a and CD79b ITAMs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy. Immunity 35, 746-756 (2011).
161. Desjarlais, J. R. & Lazar, G. A. Modulation of antibody effector function. Exp. Cell Res. 317, 1278-1285 (2011).
162. Bakema, J. E. et al. Targeting FcαRI on polymorphonuclear cells induces tumor cell killing through autophagy. J. Immunol. 187, 726-732 (2011).
163. Bakema, J. E. & van Egmond, M. Immunoglobulin A: a next generation of therapeutic antibodies? MAbs 3, 352-361 (2011).
164. Sondermann, P., Huber, R. & JacobCrystal, U. Structure of the soluble form of the human Fcγ-receptor IIb: a new member of the immunoglobulin superfamily at 1.7 Å resolution. EMBO J. 18, 1095-1103 (1999).
165. Harris, L. J., Larson, S. B., Hasel, K. W. & McPherson, A. Refined structure of an intact IgG2a monoclonal antibody. 36, 1581-1597 (1997).
166. Zhao, W. et al. FcγRIIa, not FcγRIIb, is constitutively and functionally expressed on skin-derived human mast cells. J. Immunol. 177, 694-701 (2006).
167. Kepley, C. L. et al. Co-aggregation of FcγRII with FcεRI on human mast cells inhibits antigen-induced secretion and involves SHIP-Grb2-Dok complexes. J. Biol. Chem. 279, 35139-35149 (2004).
168. White, A. L. et al. Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J. Immunol. 187, 1754-1763 (2011).
169. Wilson, N. S. et al. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 19, 101-113 (2011).